5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2

Journal of Medicinal Chemistry

Volumn 54, Issue 24, 2011, Pages 8517-8525

  Lee, Hsueh Yun ^a   Chang, Jang Yang ^b   Nien, Chih Ying ^a   Kuo, Ching Chuan ^b   Shih, Kuang Hsing ^c   Wu, Chun Hsein ^d   Chang, Chi Yen ^b   Lai, Wen Yang ^b   Liou, Jing Ping ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^d WU CHUN HSEIN OB/GYN Clinic   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3,4,5 TRIMETHOXYBENZOYL 6 METHOXYQUINOLINE DERIVATIVE; 5 AMINO 5 METHOXYQUINOLINE; 5 CHLORO 6 METHOXY 2 METHYLQUINOLINE; AMINE; ETHER; ETOPOSIDE; PACLITAXEL; PROTEIN INHIBITOR; QUINOLINE DERIVATIVE; SULFIDE; SULFONE; TUBULIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANTIPROLIFERACTION ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CELL STRAIN HT29; CELL STRAIN KB; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; MICROTUBULE; MULTIDRUG RESISTANCE; PROTEIN POLYMERIZATION;

AMINOQUINOLINES; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLCHICINE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROXYQUINOLINES; QUINOLINES; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES; TUBULIN MODULATORS;

EID: 84055176276     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201031f     Document Type: Article

References (49)

1. (a) Li, Q.; Sham, H. L. Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancer. Expert Opin. Ther. Pat. 2002, 12, 1663-1702.
2. (b) Jordan, A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle. Med. Res. Rev. 1998, 18, 259-296.
3. (c) Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. Medicinal chemistry of combretastatin A4: Present and future directions. J. Med. Chem. 2006, 49, 3033-3044.
4. (d) Hsieh, H. P.; Liou, J. P.; Mahindroo, N. Pharmaceutical design of antimitotic agents based on combretastatins. Curr. Pharm. Des. 2005, 11, 1655-1677.
5. (a) Hamel, E. Antimitotic natural products and their interactions with tubulin. Med. Res. Rev. 1996, 16, 207-231.
6. (b) Messaoudi, S.; Téguier, B.; Hamze, A.; Provot, O.; Peyrat, J. F.; De Losada, J. R.; Liu, J. M.; Bignon, J.; Wdzieczak-Bakala, J.; Thoret, S.; Dubois, J.; Brion, J. D.; Alami, M. Isocombretastatins A versus combretastatins A: The forgotten isoCA-4 isomer as a highly promising cytotoxic and antitubulin agent. J. Med. Chem. 2009, 52, 4538-4542.
7. (c) Fortin, S.; Wei, L.; Moreau, E.; Lacroix, J.; Côté, M. F.; Petitclerc, E.; Kotra, L. P.; C.-Gaudreault, R. Design, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)-benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4. J. Med. Chem. 2011, 54, 4559-4580.
8. (d) Combes, S.; Barbier, P.; Douillard, S.; McLeer-Florin, A.; Bourgarel-Rey, V.; Pierson, J.-T.; Fedorov, A. Y.; Finet, J.-P.; Boutonnat, J.; Peyrot, V. Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2. J. Med. Chem. 2011, 54, 3153-3162.
9. (e) Gangjee, A.; Zhao, Y.; Lin, L.; Raghavan, S.; Roberts, E. G.; Risinger, A. L.; Hamel, E.; Mooberry, S. L. Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance. J. Med. Chem. 2010, 53, 8116-8128.
10. (f) Romagnoli, R.; Baraldi, P. G.; Andrea Brancale, A.; Ricci, A.; Hamel, E.; Bortolozzi, R.; Basso, G.; Viola, G. Convergent synthesis and biological evaluation of 2-amino-4-(3′,4′,5′-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents. J. Med. Chem. 2011, 54, 5144-5153.
11. (g) Flynn, B. L.; Gill, G. S.; Grobelny, D. W.; Chaplin, J. H.; Paul, D.; Leske, A. F.; Lavranos, T. T.; Chalmers, D. K.; Charman, S. A.; Kostewicz, E.; Shackleford, D. M.; Morizzi, J.; Hamel, E.; Jung, K.; Kremmidiotis, G. Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimeth-oxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J. Med. Chem. 2011, 54, 6014-6027.
12. (h) Flynn, B. L.; Hamel, E.; Jung, M. K. A one-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization. J. Med. Chem. 2002, 45, 2670-2673.
13. (a) Rustin, G. J.; Shreeves, G.; Nathan, P. D.; Gaya, A.; Ganesan, T. S.; Wang, D.; Boxall, J.; Poupard, L.; Chaplin, D. J.; Stratford, M. R. L.; Balkissoon, J.; Zweifel, M. A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br. J. Cancer 2010, 102, 1355-1360.
14. (b) Mita, M. M.; Spear, M. A.; Yee, L. K.; Mita, A. C.; Heath, E. I.; Papadopoulos, K. P.; Federico, K. C.; Reich, S. D.; Romero, O.; Malburg, L.; Pilat, M.-J.; Lloyd, G. K.; Neuteboom, S. T. C.; Cropp, G.; Ashton, E.; LoRusso, P. M. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin (NPI-2358) in patients with solid tumors or lymphomas. Clin. Cancer Res. 2010, 16, 5892-5899.
15. (c) Lickliter, J. D.; Francesconi, A. B.; Smith, G.; Burge, M.; Coulthard, A.; Rose, S.; Griffin, M.; Milne, R.; McCarron, J.; Yeadon, T.; Wilks, A.; Cubitt, A.; Wyld, D. K.; Vasey, P. A. Phase I trial of CYT997, a novel cytotoxic and vascular disrupting agent. Br. J. Cancer 2010, 103, 597-606.
16. (a) Pettit, G. R.; Temple, C. J.; Narayanan, V. L.; Varma, R.; Simpson, M. J.; Boyd, M. R.; Rener, G. A.; Bansal, N. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anti-Cancer Drug Des. 1995, 10, 299-309.
17. (b) Dark, G. G.; Hill, S. A.; Prise, V. E.; Tozer, G. M.; Pettit, G. R.; Chaplin, D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997, 57, 1829-1834.
18. (c) Siemann, D. W.; Bibby, M. C.; Dark, G. G.; Dicker, A. P.; Eskens, F. A. L. M.; Horsman, M. R.; Marme, D.; LoRusso, P. M. Differentiation and definition of vascular-targeted therapies. Clin. Cancer Res. 2005, 11, 416-420.
19. (d) Tozer, G. M.; Kanthou, C.; Baguley, B. C. Disrupting tumour blood vessels. Nat. Rev. Cancer 2005, 5, 423-435.
20. (e) Patterson, D. M.; Rustin, G. J. S. Vascular damaging agents. Clin. Oncol. 2007, 19, 443-456.
21. (f) Tozer, G. M.; Akerman, S.; Cross, N. A.; Barber, P. R.; Björndahl, M. A.; Greco, O.; Harris, S.; Hill, S. A.; Honess, D. J.; Ireson, C. R.; Pettyjohn, K. L.; Prise, V. E.; Reyes-Aldasoro, C. C. Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. Cancer Res. 2008, 68, 2301-2311.
22. (g) Siemann, D. W.; Chaplin, D. J.; Walicke, P. A. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin. Invest. Drugs 2009, 18, 189-197.
23. (a) Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; Hatanaka, T.; Morinaga, Y.; Nihei, Y.; Ohishi, K.; Suga, Y.; Akiyama, Y.; Tsuji, T. Novel combretastatin analogues effective against murine solid tumors: Design and structure-activity relationships. J. Med. Chem. 1998, 41, 3022-3032.
24. (b) Delmonte, A.; Sessa, C. AVE8062: A new combretastatin derivative vascular disrupting agent. Expert Opin. Invest. Drugs 2009, 18, 1541-1548.
25. Liou, J. P.; Wu, Z. Y.; Kuo, C. C.; Chang, C. Y.; Lu, P. Y.; Chen, C. M.; Hsieh, H. P.; Chang, J. Y. Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors. J. Med. Chem. 2008, 51, 4351-4355.
26. Nien, C. Y.; Chen, Y. C.; Kuo, C. C.; Hsieh, H. P.; Chang, C. Y.; Wu, J. S.; Wu, S. Y.; Liou, J. P.; Chang, J. Y. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. J. Med. Chem. 2010, 53, 2309-2313.
27. Mahboobi, S.; Pongratz, H.; Hufsky, H.; Hockemeyer, J.; Frieser, M.; Lyssenko, A.; Paper, D. H.; Bürgermeister, J.; Böhmer, F. D.; Fiebig, H. H.; Burger, A. M.; Baasner, S.; Beckers, T. Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. J. Med. Chem. 2001, 44, 4535-4553.
28. Romagnoli, R.; Baraldi, P. G.; Pavani, M. G.; Tabrizi, M. A.; Preti, D.; Fruttarolo, F.; Piccagli, L.; Jung, M. K.; Hamel, E.; Borgatti, M.; Gambari, R. Synthesis and biological evaluation of 2-amino-3-(3′,4′,5′- trimethoxybenzoyl)-5-aryl thiophenes as a new class of potent antitubulin agents. J. Med. Chem. 2006, 49, 3906-3915.
29. Romagnoli, R.; Baraldi, P. G.; Carrion, M. D.; Cara, C. L.; Preti, D.; Fruttarolo, F.; Pavani, M. G.; Tabrizi, M. A.; Tolomeo, M.; Grimaudo, S.; Cristina, A. D.; Balzarini, J.; Hadfield, J. A.; Brancale, A.; Hamel, E. Synthesis and biological evaluation of 2- and 3-aminobenzo-[b]thiophene derivatives as antimitotic agents and inhibitors of tubulin polymerization. J. Med. Chem. 2007, 50, 2273-2277.
30. Wang, L.; Woods, K. W.; Li, Q.; Barr, K. J.; McCroskey, R. W.; Hannick, S. M.; Gherke, L.; Credo, R. B.; Hui, Y. H.; Marsh, K.; Warner, R.; Lee, J. Y.; Zielinski-Mozng, N.; Frost, D.; Rosemberg, S. H.; Sharm, H. L. Potent, orally active heterocycle-based combretastatin A-4 analogues: Synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J. Med. Chem. 2002, 45, 1697-1711.
31. (a) Zhang, Q.; Peng, Y.; Wang, X. I.; Keeman, S. M.; Aurora, S.; Welsh, W. J. Highly potent triazole-based tubulin polymerization inhibitors. J. Med. Chem. 2007, 50, 749-754.
32. (b) Romagnoli, R.; Baraldi, P. G.; Cruz-Lopez, O.; Lopez Cara, C.; Carrion, M. D.; Brancale, A.; Hamel, E.; Chen, L.; Bortolozzi, R.; Basso, G.; Viola, G. Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues. J. Med. Chem. 2010, 53, 4248-4258.
33. O'Boyle, N. M.; Carr, M.; Greene, L. M.; Bergin, O.; Nathwani, S. M.; McCabe, T.; Lloyd, D. G.; Zisterer, D. M.; Meegan, M. J. Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents. J. Med. Chem. 2010, 53, 8569-8584.
34. Simoni, D.; Grisolia, G.; Giannini, G.; Roberti, M.; Rondanin, R.; Piccagli, L.; Baruchello, R.; Rossi, M.; Romagnoli, R.; Invidiata, F. P.; Grimaudo, S.; Jung, M. K.; Hamel, E.; Gebbia, N.; Crosta, L.; Abbadessa, V.; Di Cristina, A.; Dusonchet, L.; Meli, M.; Tolomeo, M. Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines. J. Med. Chem. 2005, 48, 723-736.
35. Schobert, R.; Biersack, B.; Dietrich, A.; Effenberger, K.; Knauer, S.; Mueller, T. 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model. J. Med. Chem. 2010, 53, 6595-6602.
36. La Regina, G.; Edler, M. C.; Brancale, A.; Kandil, S.; Coluccia, A.; Piscitelli, F.; Hamel, E.; Martino, G. D.; Matesanz, R.; Díaz, J. F.; Scovassi, A. I.; Prosperi, E.; Lavecchia, A.; Novellino, E.; Artico, M.; Silvestri, R. Arylthioindole inhibitors of tubulin polymerization. 3. Biological evaluation, structure-activity relationships and molecular modeling studies. J. Med. Chem. 2007, 50, 2865-2874.
37. Gangjee, A.; Zhao, Y.; Lin, L.; Raghavan, S.; Roberts, E. G.; Risinger, A. L.; Hamel, E.; Mooberry, S. L. Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance. J. Med. Chem. 2010, 53, 8116-8128.
38. (a) Flynn, B. L.; Hamel, E.; Jung, M. K. One-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization. J. Med. Chem. 2002, 45, 2670-2673.
39. (b) Gastpar, R.; Goldbrunner, M.; Marko, D.; von Angerer, E. Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. J. Med. Chem. 1998, 41, 4965-4972.
40. Yamamoto, K.; Noda, K.; Yoshimura, A.; Kukuoka, M.; Furuse, K.; Niitani, H. Phase I study of E7010. Cancer Chemother. Pharmacol. 1998, 42, 124-134.
41. Liou, J. P.; Hsu, K. S.; Kuo, C. C.; Chang, C. Y.; Chang, J. Y. A novel oral indoline-sulfonamide agent, J30, exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule. J. Pharmacol. Exp. Ther. 2007, 323, 398-405.
42. Kuo, C. C.; Hsieh, H. P.; Pan, W. Y.; Chen, C. P.; Liou, J. P.; Lee, S. J.; Chang, Y. L.; Chen, L. T.; Chang, J. Y. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res. 2004, 64, 4621-4628.
43. Kremmidiotis, G.; Leske, A. F.; Lavranos, T. C.; Beaumont, D.; Gasic, J.; Hall, A.; O'Callaghan, M.; Matthews, C. A.; Flynn, B. BNC105: A novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol. Cancer Ther. 2010, 9, 1562-1573.
44. Finlay, G. J.; Baguley, B. C.; Wilson, W. R. A semiautomated microculture method for investigating growth inhibitory effect of cytotoxic compounds on exponentially growing carcinoma cells. Anal. Biochem. 1984, 139, 272-277.
45. Liou, J. P.; Chang, J. Y.; Chang, C. W.; Chang, C. Y.; Mahindroo, N.; Kuo, F. M.; Hsieh, H. P. Synthesis and structure-activity relationships of 3-aminobenzophenones as antimitotic agents. J. Med. Chem. 2004, 47, 2897-2905.
46. Bollag, D. M.; McQueney, P. A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C. M. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995, 55, 2325-2333.
47. Tahir, S. K.; Kovar, P.; Rosenberg, S. H.; Ng, S. C. Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin. BioTechniques 2000, 29, 156-160.
48. Tahir, S. K.; Han, E. K.; Credo, B.; Jae, H. S.; Pietenpol, J. A.; Scatena, C. D.; Wu-Wong, J. R.; Frost, D.; Sham, H.; Rosenberg, S. H.; Ng, S. C. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res. 2001, 61, 5480-5485.
49. Tahir, S. K.; Nukkala, M. A.; Zielinski Mozny, N. A.; Credo, R. B.; Warner, R. B.; Li, Q.; Woods, K. W.; Claiborne, A.; Gwaltney, S. L. II; Frost, D. J.; Sham, H. L.; Rosenberg, S. H.; Ng, S. C. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Mol. Cancer Ther. 2003, 2, 227-233.